Oncology PracticeFDA approves antibody-drug conjugate for advanced urothelial cancerDecember 19, 2019Genitourinary Cancer
Oncology PracticeRCC: Tivozanib beats sorafenib in later linesDecember 19, 2019Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeSingle-fraction radiation just misses mark for spinal compression reliefDecember 4, 2019Breast CancerLung CancerGenitourinary Cancer
Oncology PracticeAtezolizumab/bevacizumab may offer benefit to patients with RCCNovember 25, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Oncology PracticeCombo shows promise for checkpoint inhibitor-refractory urothelial carcinomaNovember 12, 2019Genitourinary CancerImmunotherapyImmuno-oncology
Oncology PracticeSunitinib for mRCC: Real-world experience differs somewhatNovember 7, 2019Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeEzrin negativity predicts poor prognosis in clear cell RCCOctober 31, 2019Renal Cell CarcinomaGenitourinary Cancer
Is it time to expand the use of PARP inhibitors?October 25, 2019Genitourinary CancerGynecologic Cancer
Oncology PracticeImmunotherapy enables nephrectomy with good outcomes in advanced RCCOctober 21, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Oncology PracticeSPARTAN: Apalutamide delays second progression in nonmetastatic CRPCOctober 18, 2019Genitourinary Cancer
Oncology PracticeAtezolizumab plus chemo gives slight PFS edge in mUCOctober 8, 2019Genitourinary CancerImmuno-oncology
Oncology PracticeCancer burden: Multiple metrics needed to clarify the big pictureOctober 4, 2019Breast CancerGastroenterologyMelanomaGenitourinary CancerRenal Cell CarcinomaGastrointestinal Cancer
Oncology PracticeNo difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCCOctober 2, 2019Renal Cell CarcinomaImmuno-oncologyGenitourinary Cancer
